The 2026 ACC/AHA dyslipidemia guidelines mark a major shift toward starting cholesterol treatment earlier and aiming for lower LDL targets. Using the new PREVENT-ASCVD calculator, clinicians can ...

Taking into account estimated 30-year risk of atherosclerotic cardiovascular disease (ASCVD) enables clinicians to identify which patients may benefit from starting primary-prevention strategies ...

A risk calculator that incorporates established cardiovascular risk factors and additional cardiac biomarkers, such as high-sensitivity C-reactive protein (hs-CRP) and N-terminal pro-B-type ...

The 2026 ACC/AHA dyslipidemia guidelines lower the 10-year ASCVD risk threshold for statin therapy from 7.5% to 5%, restoring LDL targets and promoting earlier intervention. The update introduces the ...

Please provide your email address to receive an email when new articles are posted on . Cardiology health care professionals expressed hesitancy in prescribing FDA-approved obesity medications to ...

Verve Therapeutics, Inc. (VERV) has been making great progress in being able to advance its pipeline, that's because it has done well to advance its main clinical candidate in the pipeline known as ...

Findings showed treatment with inclisiran led to clinically meaningful and statistically significant LDL-C lowering compared with placebo and ezetimibe. Topline results were announced from the phase 3 ...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that new clinical trial and outcomes research data will be presented at the European ...